Akebia Therapeutics, Inc.
AKBA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001517022
No open-market purchases or sales by Akebia Therapeutics, Inc. insiders were filed in the last 90 days; 170 institutions reported holding it in 13F filings for Q2 2026, worth $123.2M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $150.4M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +1 vs. previous quarter
- 170
- 13F valueReported value at the end of Q2 2026
- $123.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $236.2M
- +47.5% year over year
- Net income, FY2025
- -$5.34M
- No comparable prior period
- Free cash flow, FY2025
- $67.7M
- No comparable prior period
- Revenue, Q3 FY2026
- $36.9M
- −37.2% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $5.34M (2.3% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 23.1M
- Shares sold short
- Change
- +590.1K
- +2.6% vs. previous
- Days to cover
- 2.96
- At average daily volume
Superinvestors holding AKBA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding AKBA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Akebia Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 (view filing)4:34 PM ET | Jun 29 | 2 days | Ostrowski ErikSVP, CFO, CBO & Treasurer | SSale | −56.0K | $1.11 | −$62.2K | −8.3%616.6K after | 10b5-1 |
| Mar 5, 2026 (view filing) | Mar 4 | 1 day | Butler John P.CEO and President | PPurchase | +69.3K | $1.25 | +$86.6K | +2.1%3.37M after | |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Rucci Carolyn M.SVP, Chief Legal Officer | SSale | −69.8K | $1.39 | −$97.0K | −10.6%588.4K after | 3 lots10b5-1 |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Malabre Richard CSVP, Chief Accounting Officer | SSale | −49.5K | $1.39 | −$68.8K | −14.2%299.4K after | 2 lots10b5-1 |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Ostrowski ErikSVP, CFO, CBO & Treasurer | SSale | −35.0K | $1.39 | −$48.6K | −4.9%672.6K after | 10b5-1 |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Grund NicholasChief Commercial Officer | SSale | −84.8K | $1.39 | −$117.9K | −13.1%561.8K after | 2 lots10b5-1 |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Burke Steven KeithSVP, Chief Medical Officer | SSale | −67.7K | $1.39 | −$94.0K | −6.7%948.4K after | 3 lots10b5-1 |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Butler John P.CEO and President | SSale | −341.3K | $1.39 | −$474.4K | −9.4%3.30M after | 4 lots10b5-1 |
| Jul 1, 2025 (view filing) | Jun 30 | 1 day | Ostrowski ErikSVP, CFO, CBO & Treasurer | SSale | −41.3K | $3.67 | −$151.6K | −7.6%503.6K after | 10b5-1 |
| Jun 11, 2025 (view filing) | Jun 9 | 2 days | Malabre Richard CSVP, Chief Accounting Officer | SSale | −15.0K | $4.01 | −$60.1K | −5.3%266.9K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 170 holdersThe largest institutional positions in Akebia Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 19,986,374 | $22.8M | 0.00% | +1,293,078+6.9% | Added |
| Vanguard Capital Management LLC | 11,322,143 | $12.9M | 0.00% | +155,433+1.4% | Added |
| AQR Capital Management LLC | 9,151,524 | $10.4M | 0.00% | +7,358,904+410.5% | Added |
| Geode Capital Management, LLC | 6,727,302 | $7.67M | 0.00% | +275,050+4.3% | Added |
| State Street Corp | 5,390,853 | $6.15M | 0.00% | −6,223,153−53.6% | Reduced |
| Jacobs Levy Equity Management, Inc | 4,273,026 | $4.87M | 0.02% | +3,843,357+894.5% | Added |
| Acadian Asset Management LLC | 4,004,867 | $4.56M | 0.01% | +2,627,799+190.8% | Added |
| Goldman Sachs Group Inc | 3,689,167 | $4.21M | 0.00% | +86,340+2.4% | Added |
| Millennium Management LLC | 3,196,605 | $3.64M | 0.00% | +811,892+34.0% | Added |
| Vanguard Portfolio Management LLC | 2,533,977 | $2.89M | 0.00% | +318,536+14.4% | Added |
Holders of 5% or more of AKBA
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Akebia Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 7.20%19.2M shares | +1.10 ppfrom 6.10% | Oct 22, 20244 filings | Jan 21, 2026 | SEC |